Health Stocks in Motion

Shares of QLT (QLTI Quote) were among the worst-performing health-related stocks Thursday, dropping 11% after the biopharmaceutical company cut its sales forecast for its Visudyne eye treatment and laid out plans to eliminate up to 46% of its work force.

The company expects the job cuts -- and other restructuring plans -- to result in annual savings of about $10 million. QLT now sees 2005 Visudyne sales of $480 million to $485 million, down from an earlier forecast of $500 million to $530 million. QLT said the reduced forecast stems from near-term pressure on U.S. sales, caused by increased competition. The company plans to take a restructuring charge of about $5 million to $6 million during the fourth quarter of 2005.

QLT also plans to double the number of shares that it can buy as part of its share repurchase plan, which was initiated in May. The company intends to increase its buyback plan to $100 million from $50 million. Shares were trading down 75 cents to $6.25.

Hi-Tech Pharmacal(HITK Quote) rose 8% after the drug maker posted solid second-quarter results. The company earned $3.1 million, or 35 cents a share, up from $2.3 million, or 27 cents a share, a year ago. Sales, meanwhile, rose to $21.6 million from $16.7 million a year ago. A single analyst polled by Thomson First Call expected earnings of 30 cents a share and sales of $19.3 million. "We are very pleased with the second-quarter results," the company said. "Our generic business remains strong as we continue to see demand for many of the products launched in recent quarters."

For 2006, Hi-Tech Pharmacal sees sales growth of 15% to 20%. Shares traded up $3 to $41.52.

Shares of Neurogen(NRGN Quote) rose 9% after the company said its insomnia drug performed well in a Phase I trial. The biotech company said NG2-73 was safe and well tolerated. What's more, the company said that study investigators observed sleepiness among treated subjects. The study aimed to evaluate the safety, tolerability and pharmacokinetics of increasing oral doses of the drug given over a period of five days. "We're moving rapidly toward the initiation of our phase II transient insomnia trial with our immediate release tablet formulation," the company said. Neurogen shares were up 71 cents to $8.24.